Literature DB >> 29524631

HER4 promotes cell survival and chemoresistance in osteosarcoma via interaction with NDRG1.

Hongsheng Wang1, Wei Sun2, Mengxiong Sun2, Zeze Fu2, Chenghao Zhou2, Chongren Wang3, Dongqing Zuo2, Zifei Zhou2, Gangyang Wang2, Tao Zhang2, Jing Xu2, Jian Chen2, Zhuoying Wang2, Fei Yin2, Zhenfeng Duan4, Francis J Hornicek5, Zhengdong Cai6, Yingqi Hua7.   

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumor in children and adolescents. The abilities of chemotherapy resistance are major roadblock in the successful treatment of OS. The clarification of mechanism regarding cell survival during OS chemotherapy are important. Here, we examined HER4 expression by immunohistochemistry in a large series of OS tissues, and found HER4 expression correlated with tumor characteristics and patient survival rates. HER4 knockdown by shRNA inhibited OS cell growth and tumorigenesis, and induced cell senescence and apoptosis in vitro and in vivo. We demonstrated that HER4 expression upregulated in the adverse conditions, such as serum starvation and sphere culture. Moreover, HER4 knockdown cells became more sensitive in stressful conditions such as loss of attachment, cytotoxic agents or nutrition insufficiency. Mechanism studies revealed that HER4 interacted with NDRG1, and NDRG1 overexpression could antagonize HER4 knockdown-mediated cell growth and apoptosis in stressed conditions. There was a positive correlation between HER4 and NDRG1 immunoreactivity in OS patients. Together, our present study shows that HER4 and/or NDRG1 might play a critical role for the cell survival and chemo-resistance of OS, and could be used as potential therapeutic targets in OS.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cell growth; Chemotherapy resistance; HER4; NDRG1; Osteosarcoma

Mesh:

Substances:

Year:  2018        PMID: 29524631     DOI: 10.1016/j.bbadis.2018.03.008

Source DB:  PubMed          Journal:  Biochim Biophys Acta Mol Basis Dis        ISSN: 0925-4439            Impact factor:   5.187


  6 in total

1.  Expression and clinical significance of lncRNA BC041954 in ovarian cancer.

Authors:  Yan-Ming Lu; Ya-Ru Guo; Meng-Ya Zhou; Yue Wang
Journal:  Exp Ther Med       Date:  2022-04-26       Impact factor: 2.751

2.  Multifaceted and Intricate Oncogenic Mechanisms of NDRG1 in Head and Neck Cancer Depend on Its C-Terminal 3R-Motif.

Authors:  Guo-Rung You; Joseph T Chang; Hsiao-Fan Li; Ann-Joy Cheng
Journal:  Cells       Date:  2022-05-07       Impact factor: 7.666

Review 3.  Advanced development of ErbB family-targeted therapies in osteosarcoma treatment.

Authors:  Wei Wang; Hua-Fu Zhao; Teng-Fei Yao; Hao Gong
Journal:  Invest New Drugs       Date:  2018-10-24       Impact factor: 3.850

4.  PRMT5-TRIM21 interaction regulates the senescence of osteosarcoma cells by targeting the TXNIP/p21 axis.

Authors:  Yu-Hang Li; Kui-Leung Tong; Jun-Lei Lu; Jie-Bin Lin; Zhen-Yan Li; Yuan Sang; Abdelmoumin Ghodbane; Xue-Juan Gao; Man-Seng Tam; Chang-Deng Hu; Huan-Tian Zhang; Zhen-Gang Zha
Journal:  Aging (Albany NY)       Date:  2020-02-05       Impact factor: 5.682

5.  HER4 Promotes Osteosarcoma Progression and Predicts Poor Prognosis through the PTEN-PI3K/AKT Pathway.

Authors:  Kun Ma; Chuan Zhang
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

Review 6.  An overview of resistance to chemotherapy in osteosarcoma and future perspectives.

Authors:  Dorian Yarih Garcia-Ortega; Sara Aileen Cabrera-Nieto; Haydee Sarai Caro-Sánchez; Marlid Cruz-Ramos
Journal:  Cancer Drug Resist       Date:  2022-06-23
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.